Quince Therapeutics (QNCX) Price to Earnings (2019 - 2026)

Quince Therapeutics has reported Price to Earnings for 8 years, with the latest figure at 1.48 in Q2 2026.

• On a quarterly basis, Price to Earnings fell 436.11% year-over-year to 1.48 in Q2 2026; TTM through Jun 2026 was 1.48, a 1540.78% decrease from a year earlier, with the FY2025 full-year figure at 0.15, down 102.23% from the prior year.
• Price to Earnings was 1.48 for Q2 2026 at Quince Therapeutics, down from 0.01 in the prior quarter.
• The five-year high for Price to Earnings was 0.01 in Q1 2026, with the low at 1.48 in Q2 2026.
• Average Price to Earnings over 5 years is 0.35, with a median of 0.29 recorded in 2022.
• The largest YoY upside for Price to Earnings was 107.23% in 2026 against a maximum downside of 436.11% in 2026.
• Over 5 years, Price to Earnings stood at 0.21 in 2022, then slipped by 21.89% to 0.25 in 2023, then retreated by 29.72% to 0.33 in 2024, then sank by 47.1% to 0.48 in 2025, then slumped by 205.3% to 1.48 in 2026.
• The last three Price to Earnings figures came in at 1.48 (Q2 2026), 0.01 (Q1 2026), and 0.48 (Q4 2025), per Business Quant data.